MetaVia Inc. (NASDAQ:MTVA – Free Report) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share estimates for MetaVia in a report issued on Friday, March 21st. HC Wainwright analyst E. Arce forecasts that the company will earn ($5.01) per share for the year. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($3.90) per share.
MetaVia Price Performance
Shares of MetaVia stock opened at $1.55 on Monday. MetaVia has a 1 year low of $1.29 and a 1 year high of $5.30. The stock has a 50-day simple moving average of $1.70.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
See Also
- Five stocks we like better than MetaVia
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- How to Invest in Blue Chip Stocks
- 3 ETFs to Ride the VIX Surge During Market Volatility
- What is a Death Cross in Stocks?
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
